Preliminary Total Revenue for Q3 2021 was approximately $1.2 million
Cash as of September 30, 2021 was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020
OpGen concluded search and expects to announce new CFO once appointment has been formalized
OpGen received 510(k) FDA clearance for its Acuitas AMR Gene Panel
OpGen initiated prospective multicenter clinical trial in the U.S. for the Unyvero UTI application
OpGen concluded search and expects to announce new CFO once appointment has been formalized
OpGen announced data from prospective randomized controlled multicenter clinical study using the Unyvero HPN panel for hospitalized patients with suspicion of pneumonia
OpGen filed a universal shelf registration statement on Form S-3 for up to $ 150 million
OpGen achieved key milestone in Unyvero A30 RQ development program with 10 systems now available for verification and validation testing which is ongoing
OpGen subsidiary Ares Genetics completed another project with Sandoz and continued commercial roll-out and growth of the ARESiss isolate sequencing service business
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.